Brief Summary

This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.

Trial Health

On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment

1,600

participants targeted

Target at P75+ for all trials

Timeline

11mo left

Started Nov 2020

Longer than P75 for all trials

Geographic Reach

2 countries

150 active sites

Status

active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

6.5 years study duration

Study Progress87%

Nov 2020Apr 2027

First Submitted

Initial submission to the registry

March 18, 2020

Completed

1 day until next milestone

First Posted

Study publicly available on registry

March 19, 2020

Completed

8 months until next milestone

Study Start

First participant enrolled

November 11, 2020

Completed

6.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2027

Expected

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2027

Last Updated

May 13, 2026

Status Verified

April 1, 2026

Enrollment Period

6.5 years

First QC Date

March 18, 2020

Last Update Submit

May 12, 2026

Conditions

Stage III Fallopian Tube Cancer AJCC v8 Esophageal Carcinoma Anatomic Stage IV Breast Cancer AJCC v8 Multiple Myeloma Lung Non-Small Cell Carcinoma Melanoma Stage III Lung Cancer AJCC v8 Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 Clinical Stage IV Gastric Cancer AJCC v8 Fallopian Tube Carcinoma Gastric Carcinoma Stage IVB Prostate Cancer AJCC v8 Hormone Receptor-Positive Breast Carcinoma Lung Small Cell Carcinoma Malignant Solid Neoplasm Ovarian Carcinoma Metastatic Prostate Carcinoma Stage III Ovarian Cancer AJCC v8 Stage IV Ovarian Cancer AJCC v8 Invasive Breast Carcinoma Stage IV Colorectal Cancer AJCC v8 Ovarian High Grade Serous Adenocarcinoma Primary Peritoneal Carcinoma Acute Myeloid Leukemia Anatomic Stage III Breast Cancer AJCC v8 Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Stage IV Fallopian Tube Cancer AJCC v8 Stage IV Lung Cancer AJCC v8 Triple-Negative Breast Carcinoma

Outcome Measures

Primary Outcomes (3)

Procure, store and distribute longitudinal biospecimens and associated clinical data
Will procure, store and distribute longitudinal biospecimens and associated clinical data for current and future cancer research in order to elucidate molecular mechanisms of sensitivity and intrinsic or acquired resistance to standard of care systemic therapies, including immunotherapy. Cases will be grouped according to patient demographics, cancer type and treatment regimen. Statistical analysis will be descriptive and will be analyzed for each Biospecimen Source Site (BSS) as well as study aggregate.
Up to 10 years
Percentage of enrolled patients by cancer type and treatment regimen overall
Will assess the percentage of enrolled patients by cancer type and treatment regimen overall and those who contribute samples to the Drug Resistance and Sensitivity Network and other approved investigators. Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate.
Until completion of biospecimen collection, up to 3 years
Percentage of minority and underserved study participants accrued
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate.
Until completion of biospecimen collection, up to 3 years

Secondary Outcomes (7)

Pan-cancer gene panel tumor next generation sequencing test
Until completion of biospecimen collection, up to 3 years
Cancer Research Data Commons, The Cancer Imaging Archive and database of Genotypes and Phenotypes data contribution
Until completion of biospecimen collection, up to 3 years
Percentage of minority and underserved study participants accrued
Until completion of biospecimen collection, up to 3 years
Percentage of enrolled patients for whom molecular profiling is attempted
Until completion of biospecimen collection, up to 3 years
Percentage of enrolled patients for whom molecular profiling results are generated
Until completion of biospecimen collection, up to 3 years
+2 more secondary outcomes

Study Arms (1)

Observational (biospecimen collection, chart review)

Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo CT, PET/CT and/or MRI throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years.

Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingOther: Medical Chart ReviewProcedure: ParacentesisProcedure: Positron Emission Tomography

Interventions

Magnetic Resonance ImagingPROCEDURE

Undergo MRI

Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI